他拉唑帕利治疗携带DNA损伤应答改变的转移性去势抵抗性前列腺癌患者报告结局:TALAPRO-1研究结果
TALAPRO-1是一项单臂2期研究,评估他拉唑帕利在既往接受过1至2种紫杉类化疗且新型内分泌治疗后进展的转移性去势抵抗性前列腺癌(mCRPC)且携带DNA损伤应答(DDR)/同源重组修复(HRR)改变患者中的患者报告结局。97例可评估患者(BRCA1/2突变56例)中,EQ-5D-5L指数、EQ-5D视觉模拟量表评分及最严重疼痛均较基线改善,12个月时最严重疼痛未恶化的概率为84%(BRCA1/2亚组83%)。
要点
- 他拉唑帕利治疗后EQ-5D-5L指数较基线改善:全部患者0.05(95%CI 0.01,0.08),BRCA1/2亚组0.07(95%CI 0.03,0.10)。
- EQ-5D视觉模拟量表评分较基线改善:全部患者5.42(95%CI 2.65,8.18),BRCA1/2亚组4.74(95%CI 1.07,8.41)。
- 最严重疼痛较基线改善:全部患者-1.08(95%CI -1.52,-0.65),BRCA1/2亚组-1.15(95%CI -1.67,-0.62)。
核心结论
- 在经重度治疗的携带DDR/HRR改变的mCRPC男性中,他拉唑帕利与全部患者及BRCA1/2亚组健康相关生活质量改善相关。
- 在两个患者组中,最严重疼痛均较基线改善,且他拉唑帕利治疗后最严重疼痛未恶化的概率较高。
研究设计与样本
- TALAPRO-1为单臂2期研究,纳入携带直接或间接参与HRR的DDR改变的mCRPC男性,既往接受过1至2种紫杉类化疗方案治疗晚期前列腺癌,且mCRPC在一种或多种新型内分泌药物后进展。
- 患者报告结局(PRO)人群包括在研究结束前完成基线及至少一次基线后评估的男性,共97例接受他拉唑帕利治疗,其中BRCA1/2突变56例。
主要发现
- EQ-5D-5L指数较基线平均变化(95%CI):全部患者0.05(0.01,0.08),BRCA1/2亚组0.07(0.03,0.10)。
- EQ-5D视觉模拟量表评分较基线平均变化(95%CI):全部患者5.42(2.65,8.18),BRCA1/2亚组4.74(1.07,8.41)。
- 最严重疼痛较基线估计总体平均变化(95%CI):全部患者-1.08(-1.52,-0.65),BRCA1/2亚组-1.15(-1.67,-0.62)。
- 至第12个月时未经历最严重疼痛恶化的概率:全部患者84%,BRCA1/2亚组83%。
关键数值与推荐
- PRO人群为完成基线及至少一次基线后评估的男性,共97例,其中BRCA1/2突变56例。
- 纵向混合效应模型假设非结构化协方差矩阵,用于估计全部患者及BRCA1/2突变患者疼痛与总体健康状况较基线的平均变化(95%CI)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Talazoparib has shown antitumor activity with a manageable safety profile in men with metastatic castration-resistant prostate cancer (mCRPC) and DNA damage response (DDR)/homologous recombination repair (HRR) alterations. OBJECTIVE: To evaluate patient-reported health-related quality of life (HRQoL) and pain in patients who received talazoparib in the TALAPRO-1 study, with a special interest in patients harboring breast cancer susceptibility gene 1 or 2 (BRCA1/2) mutations. DESIGN, SETTING, AND PARTICIPANTS: TALAPRO-1 is a single-arm, phase 2 study in men with mCRPC DDR alterations either directly or indirectly involved in HRR, who previously received one to two taxane-based chemotherapy regimens for advanced prostate cancer and whose mCRPC progressed on one or more novel hormonal agents. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Men completed the European Quality-of-life Five-dimension Five-level scale (EQ-5D-5L), EQ-5D visual analog scale (VAS), and Brief Pain Inventory-Short Form at predefined time points during the study. The patient-reported outcome (PRO) population included men who completed a baseline and one or more postbaseline assessments before study end. Longitudinal mixed-effect models assuming an unstructured covariance matrix were used to estimate the mean (95% confidence interval [CI]) change from baseline for pain and general health status measurements among all patients and patients with BRCA1/2 mutations. RESULTS AND LIMITATIONS: In the 97 men in the PRO population treated with talazoparib (BRCA1/2, n = 56), the mean (95% CI) EQ-5D-5L Index improved (all patients, 0.05 [0.01, 0.08]; BRCA1/2 subset, 0.07 [0.03, 0.10]), as did the EQ-5D VAS scores (all patients, 5.42 [2.65, 8.18]; BRCA1/2 subset, 4.74 [1.07, 8.41]). Improvements in the estimated overall change from baseline (95% CI) in the mean worst pain were observed in all patients (-1.08 [-1.52, -0.65]) and the BRCA1/2 subset (-1.15 [-1.67, -0.62]). The probability of not having had experienced deterioration of worst pain by month 12 was 84% for all patients and 83% for the BRCA1/2 subset. CONCLUSIONS: In heavily pretreated men with mCRPC and DDR/HRR alterations, talazoparib was associated with improved HRQoL in all patients and the BRCA1/2 subset. In both patient groups, worst pain improved from baseline and the probability of not experiencing a deterioration in worst pain with talazoparib was high. PATIENT SUMMARY: We show that talazoparib was associated at least with no change or improvements in health-related quality of life (HRQoL) and pain burden in men with metastatic castration-resistant prostate cancer and DNA damage response/homologous recombination repair gene alterations in the TALAPRO-1 study. These findings in patient-reported HRQoL and pain complement the antitumor activity and tolerability profile of talazoparib.
引用
- Saad F, de Bono J, Barthélémy P, et al. Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1. Eur Urol. 2022. PMID: 35750582. doi:10.1016/j.eururo.2022.05.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。